Vaso (VASO) AI Stock Analysis

• Market Cap: $20.21M
• Dividend Yield: N/A
• Average Volume (3M): 98.46K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.20
• Revenue Growth: 9.14%
• EPS Growth: N/A
• Country: US
• Employees: 298
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): 0.01
• Shares Outstanding: 175,753,040
• 10 Day Avg. Volume: 66,687
• 30 Day Avg. Volume: 98,461
• PEG Ratio: -0.28
• Price to Book (P/B): 0.76
• Price to Sales (P/S): 0.24
• P/FCF Ratio: 11.50
• Enterprise Value/Market Cap: -0.34
• Enterprise Value/Revenue: -0.08
• Enterprise Value/Gross Profit: -0.13
• Enterprise Value/Ebitda: -1.93
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 61 Neutral
• Price Target: $0.00 ▼(-100.00% Downside)

The overall stock score is primarily influenced by stable financial performance and reasonable valuation. However, technical analysis indicates overbought conditions, suggesting potential downside risk. The lack of earnings call data and corporate events means these factors did not influence the score.

Positive Factors

Revenue Growth

Consistent revenue growth reflects Vaso's ability to maintain its market presence and adapt its offerings to meet healthcare needs, supporting long-term business stability.

Cash Flow Improvement

Improved cash flow generation enhances Vaso's financial flexibility, enabling investment in growth opportunities and strategic initiatives, strengthening its long-term prospects.

Strong Balance Sheet

A strong balance sheet with low leverage reduces financial risk, providing a solid foundation for sustainable growth and resilience against economic fluctuations.

Negative Factors

Negative Profit Margin

A negative profit margin indicates challenges in profitability, which could hinder Vaso's ability to reinvest in its business and maintain competitive positioning over time.

Operational Inefficiencies

Operational inefficiencies can erode profitability and limit Vaso's ability to scale effectively, potentially impacting long-term competitive advantage and market share.

Subsidiary Sale

While the sale may provide capital for strategic initiatives, divesting a business segment could reduce diversification and revenue streams, impacting long-term growth potential.

Vaso Business Overview & Revenue Model

Company Description

Vaso Corporation, together with its subsidiaries, operates in the healthcare equipment and information technology industries in the United States and internationally. The company operates through three segments: IT, Professional Sales Service, and Equipment. The IT segment primarily focuses on healthcare IT and managed network technology services. This segment offers managed diagnostic imaging applications, managed network infrastructure, managed network transport, and managed security services. The Professional Sales Service segment principally focuses on the sale of healthcare capital equipment for General Electric Healthcare (GEHC) into the health provider middle market. Its offerings include GEHC diagnostic imaging capital equipment, GEHC service agreements, GEHC training, and GEHC and third-party financial services. The Equipment segment primarily focuses on the design, manufacture, sale, and service of proprietary medical devices. This segment offers Biox series Holter monitors and ambulatory blood pressure recorders; ARCS series analysis, reporting, and communication software for ECG and blood pressure; MobiCare multi-parameter wireless vital-sign monitoring systems; and Enhanced External Counterpulsation therapy systems that are used for non-invasive, outpatient treatment of ischemic heart disease. The company was formerly known as Vasomedical, Inc. and changed its name to Vaso Corporation in November 2016. Vaso Corporation was incorporated in 1987 and is headquartered in Plainview, New York.

How the Company Makes Money

Vaso generates revenue through multiple streams, primarily by offering subscription-based services for its telehealth platforms, which healthcare providers pay for to access and utilize the technology in their practices. Additionally, the company earns income from the sale of its medical devices and remote monitoring equipment. Key partnerships with healthcare organizations and technology companies enhance Vaso's reach and capabilities, further contributing to its revenue through collaborative projects and joint ventures. Furthermore, Vaso may also explore funding opportunities, grants, and investments in healthcare innovations that bolster its financial performance.

Vaso Financial Statement Overview

Summary

Vaso exhibits a stable financial position with strong equity and improving cash flow metrics. Revenue growth is consistent, but the negative net profit margin raises concerns about profitability. The company maintains low leverage, which mitigates financial risk, but operational efficiency needs attention to enhance margins.

Income Statement

Vaso's income statement shows a stable revenue growth rate of 2.17% TTM, indicating consistent performance. However, the net profit margin has turned negative in the TTM period, suggesting challenges in maintaining profitability. The gross profit margin remains healthy at approximately 59.77%, but the declining EBIT and EBITDA margins highlight potential operational inefficiencies.

Balance Sheet

The balance sheet reflects a strong equity position with a low debt-to-equity ratio of 0.11 TTM, indicating financial stability and low leverage risk. Return on equity has improved to 9.49% TTM, showcasing effective use of equity to generate profits. The equity ratio is robust, further emphasizing the company's solid financial foundation.

Cash Flow

Vaso's cash flow statement reveals a significant improvement in free cash flow growth at 11.88% TTM, demonstrating enhanced cash generation capabilities. The operating cash flow to net income ratio is moderate, suggesting reasonable cash conversion efficiency. The free cash flow to net income ratio exceeds 1, indicating strong cash flow relative to earnings.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	89.11M	86.77M	81.02M	80.02M	75.58M	69.85M
Gross Profit	54.28M	52.05M	50.59M	48.48M	43.13M	38.57M
EBITDA	3.60M	2.10M	5.95M	8.38M	6.66M	3.23M
Net Income	2.59M	951.00K	4.80M	11.87M	6.10M	358.00K
Balance Sheet
Total Assets	84.47M	82.94M	75.76M	72.66M	52.36M	50.38M
Cash, Cash Equivalents and Short-Term Investments	34.86M	26.27M	25.32M	20.32M	6.65M	7.58M
Total Debt	2.03M	2.38M	2.06M	1.81M	1.39M	13.19M
Total Liabilities	24.64M	55.24M	48.91M	49.78M	41.05M	45.29M
Stockholders Equity	28.24M	27.70M	26.84M	22.88M	11.31M	5.08M
Cash Flow
Free Cash Flow	8.79M	1.83M	4.57M	13.85M	7.40M	4.93M
Operating Cash Flow	8.64M	3.28M	5.30M	14.42M	7.82M	5.93M
Investing Cash Flow	-865.00K	11.73M	-5.66M	-8.42M	-260.00K	-575.00K
Financing Cash Flow	224.00K	-89.00K	-134.00K	-230.00K	-8.33M	-553.00K

Vaso Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.16
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VASO, the sentiment is Positive. The current price of 0.16 is above the 20-day moving average (MA) of 0.13, above the 50-day MA of 0.12, and above the 200-day MA of 0.13, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 67.22 is Neutral, neither overbought nor oversold. The STOCH value of 47.54 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VASO.

Vaso Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VASO	61 Neutral	$20.21M	-67.65	-1.14%	―	9.14%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
VSEE	39 Underperform	$17.36M	-0.24	―	―	187.24%	82.90%
BEAT	34 Underperform	$56.61M	-2.37	-792.01%	―	―	4.31%
HCTI	27 Underperform	$15.45M	-0.02	-182.56%	―	-21.88%	68.40%